Francesc Graus1, Josep Dalmau. 1. Service of Neurology, Hospital Clinic, Universitat de Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer, Barcelona, Spain. fgraus@clinic.ub.es
Abstract
PURPOSE OF REVIEW: This review describes relevant advances in paraneoplastic neurological syndromes (PNS) with emphasis on particular syndromes and the impact of antibodies against surface antigens in their management. RECENT FINDINGS: PNS may present with symptoms that do not raise the suspicion of a paraneoplastic origin. The best example is anti-N-methyl-D-aspartate receptor encephalitis that in adult women frequently associates with ovarian teratoma. An electroencephalogram pattern described as 'extreme delta brush' was recently identified in 30% of patients with this disorder. Isolated myelopathy may have a paraneoplastic origin associated with amphiphysin or CV2 (CRMP5) antibodies. Jaw dystonia and laryngospasm can be the predominant symptom of the brainstem encephalitis associated with Ri antibodies. γ-Aminobutyric acid (GABA)(B) receptor antibodies are the most common antibodies found in patients with limbic encephalitis and small cell lung cancer, and contactin-associated protein 2 antibodies in patients with Morvan's syndrome and thymoma. Lastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma. SUMMARY: The number of antibodies relevant to PNS is now expanded to those against surface antigens. These antibodies do not confirm the paraneoplastic origin of the syndrome but predict a better response to immunotherapy.
PURPOSE OF REVIEW: This review describes relevant advances in paraneoplastic neurological syndromes (PNS) with emphasis on particular syndromes and the impact of antibodies against surface antigens in their management. RECENT FINDINGS: PNS may present with symptoms that do not raise the suspicion of a paraneoplastic origin. The best example is anti-N-methyl-D-aspartate receptor encephalitis that in adult women frequently associates with ovarian teratoma. An electroencephalogram pattern described as 'extreme delta brush' was recently identified in 30% of patients with this disorder. Isolated myelopathy may have a paraneoplastic origin associated with amphiphysin or CV2 (CRMP5) antibodies. Jaw dystonia and laryngospasm can be the predominant symptom of the brainstem encephalitis associated with Ri antibodies. γ-Aminobutyric acid (GABA)(B) receptor antibodies are the most common antibodies found in patients with limbic encephalitis and small cell lung cancer, and contactin-associated protein 2 antibodies in patients with Morvan's syndrome and thymoma. Lastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma. SUMMARY: The number of antibodies relevant to PNS is now expanded to those against surface antigens. These antibodies do not confirm the paraneoplastic origin of the syndrome but predict a better response to immunotherapy.
Authors: Sarah E Schmitt; Kimberly Pargeon; Eric S Frechette; Lawrence J Hirsch; Josep Dalmau; Daniel Friedman Journal: Neurology Date: 2012-08-29 Impact factor: 9.910
Authors: Sean J Pittock; Joseph E Parisi; Andrew McKeon; Shanu F Roemer; Claudia F Lucchinetti; K Meng Tan; B Mark Keegan; Samuel F Hunter; Paul R Duncan; Joachim M Baehring; Joseph Y Matsumoto; Vanda A Lennon Journal: Arch Neurol Date: 2010-09
Authors: John E Greenlee; Susan A Clawson; Kenneth E Hill; Blair L Wood; Ikuo Tsunoda; Noel G Carlson Journal: J Neuropathol Exp Neurol Date: 2010-10 Impact factor: 3.685
Authors: Christian Geis; Andreas Weishaupt; Stefan Hallermann; Benedikt Grünewald; Carsten Wessig; Thomas Wultsch; Andreas Reif; Nadiya Byts; Marcus Beck; Sibylle Jablonka; Michael K Boettger; Nurcan Üçeyler; Wernher Fouquet; Manfred Gerlach; Hans-Michael Meinck; Anna-Leena Sirén; Stephan J Sigrist; Klaus V Toyka; Manfred Heckmann; Claudia Sommer Journal: Brain Date: 2010-09-30 Impact factor: 13.501
Authors: M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren Journal: Eur J Neurol Date: 2010-09-29 Impact factor: 6.089
Authors: A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser Journal: Clin Infect Dis Date: 2013-07-15 Impact factor: 9.079